Amid a boom in genetic testing that aims to predict a person’s response to medication, the Food and Drug Administration has been quietly pressuring a handful of companies to stop reporting results to patients about how their genes may interact with specific drugs.
The agency’s concern? That unsupported claims about gene-drug links could be dangerous, if they spur patients to start, stop, or switch medications in ways that aren’t appropriate.
About the Author Reprints
